{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T10:48:10Z","timestamp":1789555690104,"version":"build-2803163510"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Parasitology"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.exppara.2015.06.005","type":"journal-article","created":{"date-parts":[[2015,6,23]],"date-time":"2015-06-23T06:21:37Z","timestamp":1435040497000},"page":"12-22","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Could miltefosine be used as a therapy for toxoplasmosis?"],"prefix":"10.1016","volume":"157","author":[{"given":"Maha M.","family":"Eissa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf M.A.","family":"Barakat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eglal I.","family":"Amer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Layla K.","family":"Younis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exppara.2015.06.005_bib1","first-page":"1","article-title":"The histopathological picture of concomitant infection with Leishmania major and Toxoplasma gondii in albino mice","volume":"19","author":"Abdel Wahab","year":"1989","journal-title":"J.\u00a0Egypt. Soc. Parasitol."},{"key":"10.1016\/j.exppara.2015.06.005_bib2","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/BF01690096","article-title":"Use of rifabutin in combination with atovaquone, clindamycin, pyrimethamine, or sulfadiazine for treatment of toxoplasmic encephalitis in mice","volume":"15","author":"Araujo","year":"1996","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.exppara.2015.06.005_bib3","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1086\/340577","article-title":"The molecular basis of sulphonamide resistance in Toxoplasma gondii and implications for the clinical management of toxoplasmosis","volume":"185","author":"Aspinall","year":"2002","journal-title":"J.\u00a0Infect. Dis."},{"issue":"127","key":"10.1016\/j.exppara.2015.06.005_bib4","first-page":"302","article-title":"The effect of clindamycin and sulfadiazine on experimental murine model with acute toxoplasmosis","volume":"56","author":"Barakat","year":"2010","journal-title":"Assiut Vet. Med. J."},{"key":"10.1016\/j.exppara.2015.06.005_bib5","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.bcmd.2010.04.007","article-title":"PDCD2, a protein whose expression is repressed by BCL6,induces apoptosis in human cells by activation of the caspasecascade","volume":"45","author":"Baron","year":"2010","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.exppara.2015.06.005_bib6","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2174\/138920009787846332","article-title":"Cellular transport and lipid interactions of miltefosine","volume":"10","author":"Barratt","year":"2009","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.exppara.2015.06.005_bib7","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1194\/jlr.R800080-JLR200","article-title":"Bioactive sphingolipids: metabolism and function","volume":"50","author":"Bartke","year":"2009","journal-title":"J.\u00a0Lipid Res. Suppl."},{"key":"10.1016\/j.exppara.2015.06.005_bib8","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/jac\/dki417","article-title":"In\u00a0vitro activity of hexadecylphosphocholine (miltefosine) against metronidazole-resistant and susceptible strains of Trichomonasvaginalis","volume":"57","author":"Blaha","year":"2006","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.exppara.2015.06.005_bib9","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1517\/14656566.6.8.1381","article-title":"Miltefosine to treat leishmaniasis","volume":"6","author":"Berman","year":"2005","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.exppara.2015.06.005_bib10","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/BF02535556","article-title":"Distribution and metabolism of hexadecylphosphocholine in mice","volume":"22","author":"Breiser","year":"1987","journal-title":"Lipids"},{"key":"10.1016\/j.exppara.2015.06.005_bib11","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S1359-6446(03)02902-7","article-title":"Rediscovering the sweet spot in drug discovery","volume":"8","author":"Brown","year":"2003","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.exppara.2015.06.005_bib12","doi-asserted-by":"crossref","first-page":"31221","DOI":"10.1074\/jbc.M404232200","article-title":"Purine salvage pathways in the apicomplexan parasite Toxoplasma gondii","volume":"279","author":"Chaudhary","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.exppara.2015.06.005_bib13","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1039\/B816679J","article-title":"Artemisinin and its derivatives: a novel class of anti-malarial and anti-cancer agents","volume":"39","author":"Chaturvedi","year":"2010","journal-title":"Chem. Soc. Rev."},{"issue":"4","key":"10.1016\/j.exppara.2015.06.005_bib14","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1128\/AAC.05183-11","article-title":"Significant reduction of brain cysts caused by Toxoplasma gondii after treatment with spiramycin coadministered with metronidazole in a mouse model of chronic toxoplasmosis","volume":"56","author":"Chew","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.exppara.2015.06.005_bib15","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1128\/AAC.00919-06","article-title":"Inhibition of Plasmodium falciparum choline kinase by hexadecyltrimethylammonium bromide: a possible antimalarial mechanism","volume":"51","author":"Choubey","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"issue":"10","key":"10.1016\/j.exppara.2015.06.005_bib16","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.placenta.2009.08.002","article-title":"Azithromycin inhibits vertical transmission of Toxoplasma gondii in Calomys callosus (Rodentia: Cricetidae)","volume":"30","author":"Costa","year":"2009","journal-title":"Placenta"},{"key":"10.1016\/j.exppara.2015.06.005_bib17","article-title":"Akt inhibitors as an HIV-I infected macrophagespecific anti-viral therapy","volume":"5","author":"Cugh","year":"2008","journal-title":"Retrovirology"},{"key":"10.1016\/j.exppara.2015.06.005_bib18","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0001-706X(03)00194-3","article-title":"Efficacy of azithromycin in a murine toxoplasmosis model, employing a Toxoplasma gondiistrain from Turkey","volume":"88","author":"Degerli","year":"2003","journal-title":"Acta Trop."},{"key":"10.1016\/j.exppara.2015.06.005_bib19","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.pt.2010.09.001","article-title":"Piggy-backing the concept of cancer drugs for schistosomiasis treatment: a tangible perspective?","volume":"27","author":"Dissous","year":"2011","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.exppara.2015.06.005_bib20","first-page":"99","article-title":"Murine model of drug-induced reactivation of Toxoplasma gondii","volume":"40","author":"Djakovic","year":"2001","journal-title":"Acta Protozool."},{"key":"10.1016\/j.exppara.2015.06.005_bib21","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1093\/jac\/dkf251","article-title":"Efficacy of atovaquone combined with clindamycin against murineinfection with a cystogenic (Me49) strain of Toxoplasma gondii","volume":"50","author":"Djurkovi-Djakovi","year":"2002","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.exppara.2015.06.005_bib22","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ijpara.2010.09.010","article-title":"Miltefosine, a promising novel agent for schistosomiasis mansoni","volume":"41","author":"Eissa","year":"2011","journal-title":"Int. J. Parasitol."},{"issue":"73","key":"10.1016\/j.exppara.2015.06.005_bib23","article-title":"Bioactivity of miltefosine against aquatic stages of Schistosoma mansoni, Schistosoma haematobium and their snail hosts supported by scanning electron microscopy","volume":"4","author":"Eissa","year":"2011","journal-title":"Parasit. Vectors"},{"key":"10.1016\/j.exppara.2015.06.005_bib24","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ijpara.2012.02.015","article-title":"Giardia lamblia: a new target for miltefosine","volume":"42","author":"Eissa","year":"2012","journal-title":"Inter J. Parasitol."},{"key":"10.1016\/j.exppara.2015.06.005_bib25","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.exppara.2012.05.001","article-title":"Initial characterization of an autoclaved Toxoplasma vaccine in mice","volume":"131","author":"Eissa","year":"2012","journal-title":"Exp. Parasitol."},{"key":"10.1016\/j.exppara.2015.06.005_bib26","first-page":"59","article-title":"Study of the role of antioxidants in experimental toxoplasmosis","volume":"23","author":"El-Temsahy","year":"2002","journal-title":"J.\u00a0Med. Res. Inst."},{"key":"10.1016\/j.exppara.2015.06.005_bib27","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ijpara.2003.12.001","article-title":"Toxoplasma gondii lacks the enzymes required for denovo arginine biosynthesis and arginine starvation triggers cyst formation","volume":"34","author":"Fox","year":"2004","journal-title":"Int. J. Parasitol."},{"key":"10.1016\/j.exppara.2015.06.005_bib28","series-title":"Principles and Techniques of Electron Microscopy: Biological Applications","author":"Hayat","year":"2000"},{"key":"10.1016\/j.exppara.2015.06.005_bib29","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.exppara.2010.09.002","article-title":"Toxoplasma gondii: Inhibitory activity and encystation effect of securinine and pyrrolidine derivatives on Toxoplasma growth","volume":"127","author":"Holmes","year":"2011","journal-title":"Exp. Parasitol."},{"key":"10.1016\/j.exppara.2015.06.005_bib30","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/449166a","article-title":"Mission possible","volume":"449","author":"Hopkins","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.exppara.2015.06.005_bib31","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1586\/erv.10.113","article-title":"Vaccination against Toxoplasma gondii: an increasing priority for collaborative research?","volume":"9","author":"Innes","year":"2010","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.exppara.2015.06.005_bib32","doi-asserted-by":"crossref","first-page":"405","DOI":"10.4269\/ajtmh.2007.77.405","article-title":"Toxoplasma gondii infection in the United States, 1999\u20132004, decline from the prior decade","volume":"77","author":"Jones","year":"2007","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.exppara.2015.06.005_bib33","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ijpara.2003.12.009","article-title":"Toxoplasma gondii: the model apicomplexan","volume":"34","author":"Kim","year":"2004","journal-title":"Int. J. Parasitol."},{"key":"10.1016\/j.exppara.2015.06.005_bib34","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1586\/erv.09.27","article-title":"Current status of toxoplasmosis vaccine development","volume":"8","author":"Ku","year":"2009","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.exppara.2015.06.005_bib35","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/cdd.2008.150","article-title":"Classification of cell death: recommendations of the nomenclature committee on cell death","volume":"16","author":"Kroemer","year":"2009","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.exppara.2015.06.005_bib36","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00436-006-0306-9","article-title":"Subversion of innate and adaptative immune responses by Toxoplasma gondii","volume":"100","author":"Lang","year":"2007","journal-title":"Parasitol. Res."},{"key":"10.1016\/j.exppara.2015.06.005_bib37","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1128\/AAC.01428-06","article-title":"In\u00a0vitro bactericidal activity of the antiprotozoal drug miltefosine against Streptococcus pneumoniae and other pathogenic streptococci","volume":"51","author":"Llull","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.exppara.2015.06.005_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0166-6851(00)00278-4","article-title":"Ether-lipid (alkyl-phospholipid) metabolism and the mechanism of action of ether\u2013lipid analogues in Leishmania","volume":"111","author":"Lux","year":"2000","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.exppara.2015.06.005_bib39","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/BF00695989","article-title":"Distribution of hexadecylphosphocholine and octadecyl-methyl-glycero-3-phosphocholine in rat tissues during steady-state treatment","volume":"31","author":"Marschner","year":"1992","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"3","key":"10.1016\/j.exppara.2015.06.005_bib40","first-page":"419","article-title":"The effect of sulfomethoxypyrazine-pyrimethamine therapy on the fine structure of Toxoplasma gondii-cysts in the brain of Mastomys natalensis. Scanning and transmission electron microscopical investigations","volume":"238","author":"Matuschka","year":"1977","journal-title":"Zentralbl Bakteriol. Orig. A"},{"key":"10.1016\/j.exppara.2015.06.005_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0166-6851(00)00184-5","article-title":"Characterization of cytochrome b from Toxoplasma gondii and Q(o) domain mutations as a mechanism of atovaquone-resistance","volume":"108","author":"McFadden","year":"2000","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.exppara.2015.06.005_bib42","first-page":"81S","article-title":"Cytochrome b mutation identified in a decoquinate-resistant mutant of Toxoplasma gondii","volume":"46","author":"McFadden","year":"1999","journal-title":"J.\u00a0Eukaryot. Microbiol."},{"key":"10.1016\/j.exppara.2015.06.005_bib43","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.4049\/jimmunol.140.5.1632","article-title":"Subcutaneous and intestinal vaccination with tachyzoites of Toxoplasma gondii and acquisition of immunity to per oral and congenital Toxoplasma challenge","volume":"140","author":"Mcleod","year":"1988","journal-title":"J.\u00a0Immunol."},{"issue":"3","key":"10.1016\/j.exppara.2015.06.005_bib44","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/01.inf.0000202070.59190.9a","article-title":"Severe sulfadiazine hypersensitivity in a child with reactivated congenital toxoplasmic chorioretinitis","volume":"25","author":"McLeod","year":"2006","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.exppara.2015.06.005_bib45","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/S0140-6736(04)16412-X","article-title":"Toxoplasmosis","volume":"363","author":"Montoya","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.exppara.2015.06.005_bib46","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1086\/590149","article-title":"Management of Toxoplasma gondii infection during pregnancy","volume":"47","author":"Montoya","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.exppara.2015.06.005_bib47","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.pt.2009.12.002","article-title":"Anticancer agents against malaria: time to revisit?","volume":"26","author":"Nazila","year":"2010","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.exppara.2015.06.005_bib48","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s10495-013-0832-8","article-title":"Apoptosis-like cell death pathways in the unicellular parasite Toxoplasma gondii following treatment with apoptosis inducers and chemotherapeutic agent: a proof-of-concept study","volume":"18","author":"Ni Nyoman","year":"2013","journal-title":"Apoptosis"},{"key":"10.1016\/j.exppara.2015.06.005_bib49","series-title":"Hexadecylphosphocholin (Miltefosin) und seine antiparasit\u00e4re Wirkung gegen Toxoplasma gondii in Zellkultur und im Mausmodell","author":"Otto","year":"2011"},{"issue":"2","key":"10.1016\/j.exppara.2015.06.005_bib50","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s00436-011-2515-0","article-title":"Efficacy of miltefosine for topical treatment of Acanthamoeba keratitis in Syrian hamsters","volume":"110","author":"Polat","year":"2012","journal-title":"Parasitol. Res."},{"key":"10.1016\/j.exppara.2015.06.005_bib51","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1111\/j.1365-2958.2010.07181.x","article-title":"Cathepsin L occupies a vacuolar compartment and is a protein maturase within the endo\/exocytic system of Toxoplasma gondii","volume":"76","author":"Parussini","year":"2010","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.exppara.2015.06.005_bib52","doi-asserted-by":"crossref","first-page":"4994","DOI":"10.1074\/jbc.M606764200","article-title":"Cathepsin Cs are key for the intracellular survival of the protozoan parasite, Toxoplasma gondii","volume":"282","author":"Que","year":"2007","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.exppara.2015.06.005_bib53","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1096\/fj.09-148999","article-title":"Securinine induces p73-dependent apoptosis preferentially in p53-deficient colon cancer cells","volume":"24","author":"Rana","year":"2010","journal-title":"FASEB J."},{"key":"10.1016\/j.exppara.2015.06.005_bib54","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1128\/AAC.37.11.2371","article-title":"In\u00a0vivo and in\u00a0vitro activities of hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii","volume":"37","author":"Romand","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.exppara.2015.06.005_bib55","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00431-005-1665-4","article-title":"Treatment of infants with congenital toxoplasmosis: tolerability plasma concentrations of sulfadiazine and pyrimethamine","volume":"165","author":"Schmidt","year":"2006","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.exppara.2015.06.005_bib56","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1550-7408.2005.00082.x","article-title":"In\u00a0vitro activity of miltefosine and voriconazole on clinical isolates of free-living amebas: Balamuthia mandrillaris, Acanthamoeba spp., and Naegleria fowleri","volume":"53","author":"Schuster","year":"2006","journal-title":"J.\u00a0Eukaryot. Microbiol."},{"key":"10.1016\/j.exppara.2015.06.005_bib57","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1128\/AAC.45.5.1505-1510.2001","article-title":"Effects of miltefosine and other alkylphosphocholines on human intestinal parasite Entamoeba histolytica","volume":"45","author":"Seifert","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.exppara.2015.06.005_bib58","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ijpara.2003.11.009","article-title":"Mechanisms underlying the manipulation of host apoptotic pathways by Toxoplasma gondii","volume":"34","author":"Sinai","year":"2004","journal-title":"Int. J. Parasitol."},{"key":"10.1016\/j.exppara.2015.06.005_bib59","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/j.trstmh.2006.02.010","article-title":"Development of miltefosine as an oral treatment for leishmaniasis","volume":"100","author":"Sindermann","year":"2006","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.exppara.2015.06.005_bib61","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s004360050185","article-title":"Effect of immunosuppressive drug regimens on acute chronic murine toxoplasmosis","volume":"82","author":"Sumyuen","year":"1996","journal-title":"Parasitol. Res."},{"key":"10.1016\/j.exppara.2015.06.005_bib62","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.trstmh.2006.03.010","article-title":"Mechanisms of action of lysophospholipid analogues against trypanosomatid parasites","volume":"100","author":"Urbina","year":"2006","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.exppara.2015.06.005_bib63","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.2174\/138161208785294636","article-title":"Anticancer alkylphospholipids: mechanisms of action, cellular sensitivity and resistance, and clinical prospects","volume":"14","author":"Van Blitterswijk","year":"2008","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.exppara.2015.06.005_bib64","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1128\/AAC.46.3.695-701.2002","article-title":"Cytotoxic activities of alkylphosphocholines against clinical isolates of Acanthamoeba spp","volume":"46","author":"Walochnik","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.exppara.2015.06.005_bib65","doi-asserted-by":"crossref","first-page":"715","DOI":"10.4269\/ajtmh.2012.12-0100","article-title":"Treatment of granulomatous amoebic encephalitis with voriconazole and miltefosine in an immunocompetent soldier","volume":"87","author":"Webster","year":"2012","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.exppara.2015.06.005_bib66","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1128\/AAC.50.2.414-421.2006","article-title":"Hexadecylphosphocholine (miltefosine) has a broad-spectrum fungicidal activity and is efficacious in a mouse model of cryptococcosis","volume":"50","author":"Widmer","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.exppara.2015.06.005_bib67","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0163-7827(99)00004-1","article-title":"Mechanisms of action of phospholipid analogs as anticancer compounds","volume":"38","author":"Wieder","year":"1999","journal-title":"Prog. Lipid. Res."}],"container-title":["Experimental Parasitology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014489415001654?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014489415001654?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T18:17:32Z","timestamp":1691777852000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014489415001654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":66,"alternative-id":["S0014489415001654"],"URL":"https:\/\/doi.org\/10.1016\/j.exppara.2015.06.005","relation":{},"ISSN":["0014-4894"],"issn-type":[{"value":"0014-4894","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Could miltefosine be used as a therapy for toxoplasmosis?","name":"articletitle","label":"Article Title"},{"value":"Experimental Parasitology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exppara.2015.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}